TUMOR NECROSIS FACTOR α, INTERLEUKIN 1β AND DATAS OF ERYTHROPOESIS IN PATIENTS WITH CHRONIC HEART FAILURE OF ISCHEMIC GENESIS AND ANEMIA
Abstract
120 patients with CHF and anemia were exemained. CHF of II FC was found in 49 patients, III FC – in 42 and IV FC in 29 patients. All patients had standart treatment. The level of hemoglobin, MKV, MCH, MCHC, hematocrite, serum iron, ferritine, erythropoetin, tumor necrosis factor α, interleukin 1β. It was found that the level of hemoglobin and serum iron in patients with CHF of ischemic genesis was decreased and it has direct relation to increased level of proinflammatory cytokins, which increases in parallel to incerasement of erythropoetin, which reflects cytokininducted appearance of anemia in patients with CHF as a result of erythropoesis inhibition.
Downloads
References
2. Бакшеев В.И., Коломоец Н.М. // Клиническая медицина. – 2007. - №.9. - С. 27-30.
3. Гайдукова С., Выдыборец С. // Ліки України. - 2004 - № 7-8. - С. 33-36.
4. Гусева С.А., Гончаров Я.П. Анемии. -К.:«Логос». - 2004. - 408 с.
5. Дядык А.И., Багрий А.Э. Хроническая сердечная недостаточность в современной клинической практике. -Донецк. КП «Регион». - 2005. - 552 с.
6. Ермоленко В.М., Николаев А.Ю. // Тер. арх. - 1990. - № 62(11). - С.141-145.
7. Насонов Е. Л., Самсонов М. Ю. // Сердечная недостаточность. - 2000. - № 4. - Том 1.
8. Павлов А. Д., Морщакова Е. Ф. // Гематол. и трансфузиол. - 1999. - № 3. - Т. 44. - С. 30-32.
9. Петухов В.И., Быкова Е.Я., Бондарев Д.К. и др. // Гематол. и трансфузиол. - 2003. - №2. - Т. 48. - С. 36-41.
10. Терещенко С.Н. и др. // Кардиология. - 2004. - №7. - С. 73-76
11. Anand I., Florea V., Fisher L. et al. // J. Card. Failure, 2002; 8 (suppl.): 046 (abstr.).
12. Anker S.D. Mohacsi P., Coats A.J.S. et al. // Europ. Heart J., 2003; 24 (suppl.): 487 (abstr. 2592).
13. Barosi G. // Ann Hematol. - 1994. - № 68. - Р. 215-223.
14. Bolger A.P., Doehner W., Sharma R. et al. // Circulation. - 2002; 106: Suppl: II570 – II571.
15. Byrd T. F., Horwitz M. F // Clin. Invest. - 1999. - № 91. - Р. 969.
16. Chatterjee В., Nydegger U.E., Mohacsi P. // Eur. J. Heart Fail. - 2000. - Vol. 2. - № 4. - Р. 393-398.
17. Denz H., Fuchs D., Huber H. et al. // Eur. J. Haematol. - 1990. - № 44. - Р. 186.
18. Deswal A., Petersen N.J., Feldman A.M. et al. // Circulation. - 2001. - № 103. - Р. 2055-2059.
19. Engert A. J. Erythropoietin // N. Engl. J. Med. - 1991. - № 324. - Р. 1339.
20. Ezekowitz J.A., McAlister F.A., Armstrong P.W. // Circulation. - 2003. - Vol. 107. - P. 223-225.
21. Fantacci M., Bianciardi P., Caretti A. // Proc Natl Acad Sci USA. - 2006. - №103(46). - Р. 17531- 17536.
22. Fitzsimons E. J., Brock J. H. // British Med. J. - 2001. - Vol. 322. - Р. 811-815.
23. George J., Patal S., Wexler D. et al., // Arch Intern Med. - 2005. - №165. - Р. 1304-1309.
24. Guenter Weiss, M.D., and Lawrence T. Goodnough, M.D.// N Engl J Med. - 2005. - №352. - Р. 1011-1023.
25. Iversen P.O., Woldbaek P.R., Tonnessen Т., et al. // Am J. Physiol Regul. Integr. Comp. Physiol. - 2002. - № 282. - P. 166-172
26. Jelkmann W. // J Interferon Cytokine Res. - 1998. - № 18. - Р. 555-559.
27. Komajda M., Cleland J., Di Lenarda A. et al. // European Heart Journal. - 2004. - Vol. 25 (Abstract Sup-plement). - Р. 651.
28. Manolis A.S., Tzeis S., Triantafyllou K. et al. // Curr Drug Targets Cardiovasc Haematol Disord. - 2005. - № 5(5). - Р. 355-375.
29. Means R. T., Krantz S. B. // Clin. Res. - 1992. - 40. - Р. 210a.
30. Mishra Т., Mishra S., Mohanty N. et al. // Indian Heart J. - 2005 (NovDec). - 57(6). - Р. 670-674.
31. Papadaki H. A. et al. // Blood. - 2002. - Vol. 100. - Р. 474-476.
32. Rankin E. B., Biju M. P., Liu Q. et al. // J. Clin. Invest. - 2007. - № 117. - Р. 1068-1077.
33. Sharma R., Francis D.P., Pitt B. et al. // Europ. Heart J. 2004. - № 25. - Р. 1021-1028.
34. Yusuf S., Pfeffer M., Swedberg K. et al. // Lancet. - 2003. - Vol. 362. - P. 777-781.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.